356 related articles for article (PubMed ID: 31644992)
1. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
Vollmer B; Ontaneda D; Harris H; Nair K; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
J Neurol Sci; 2019 Dec; 407():116498. PubMed ID: 31644992
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
4. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL; Nair K; Sillau S; Corboy JR; Vollmer T; Alvarez E
Ann Clin Transl Neurol; 2020 Sep; 7(9):1466-1476. PubMed ID: 32767538
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL; Nair KV; Sillau S; Corboy JR; Vollmer T; Alvarez E
Ann Clin Transl Neurol; 2019 Feb; 6(2):252-262. PubMed ID: 30847358
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.
Vollmer B; Ontaneda D; Bandyopadhyay A; Cohn S; Nair K; Sillau S; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
Neurol Clin Pract; 2018 Aug; 8(4):292-301. PubMed ID: 30140580
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
[TBL] [Abstract][Full Text] [Related]
8. Persistence to oral disease-modifying therapies in multiple sclerosis patients.
Lattanzi S; Danni M; Taffi R; Cerqua R; Carlini G; Pulcini A; Provinciali L; Silvestrini M
J Neurol; 2017 Nov; 264(11):2325-2329. PubMed ID: 28831550
[TBL] [Abstract][Full Text] [Related]
9. Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study.
Diem L; Daponte A; Findling O; Miclea A; Briner M; Salmen A; Gold R; Kilidireas C; Chan A; Evangelopoulos ME; Hoepner R
Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31937596
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
Prosperini L; Lucchini M; Haggiag S; Bellantonio P; Bianco A; Buscarinu MC; Buttari F; Centonze D; Cortese A; De Giglio L; Fantozzi R; Ferraro E; Fornasiero A; Francia A; Galgani S; Gasperini C; Marfia GA; Millefiorini E; Nociti V; Pontecorvo S; Pozzilli C; Ruggieri S; Salvetti M; Sgarlata E; Mirabella M
Neurology; 2018 Jul; 91(2):e153-e161. PubMed ID: 29875218
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
[TBL] [Abstract][Full Text] [Related]
12. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
13. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
Bosco-Lévy P; Debouverie M; Brochet B; Guillemin F; Louapre C; Maillart E; Heinzlef O; Lignot S; Diez P; Abouelfath A; Lassalle R; Blin P; Droz-Perroteau C
Br J Clin Pharmacol; 2022 Mar; 88(3):1268-1278. PubMed ID: 34505304
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
16. Real-life use of oral disease-modifying treatments in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
J Neurol; 2021 Mar; 268(3):941-949. PubMed ID: 32974794
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience.
Vollmer B; Nair KV; Sillau SH; Corboy J; Vollmer T; Alvarez E
Mult Scler J Exp Transl Clin; 2017; 3(3):2055217317725102. PubMed ID: 28839949
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
20. A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
Duquette P; Yeung M; Mouallif S; Nakhaipour HR; Haddad P; Schecter R
PLoS One; 2019; 14(1):e0210417. PubMed ID: 30640935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]